HEALTH

One Brands unveils naturally-sweet One Basix Bars line at Expo

BY Michael Johnsen

One Brands, the maker of One Bars, debuted their latest innovation, One Basix Bars, at the Natural Products Expo West. One Basix Bars are naturally sweetened with no artificial flavors or preservatives and are available in three flavors: cookie dough chocolate chunk, triple chocolate chunk and peanut butter chocolate chunk.

“We know through research and consumer feedback that many people desire a naturally sweetened protein bar and One Basix Bars meets this consumer demand without sacrificing anything One Bar stands for: decadent flavors, high-quality ingredients, complete nutrition, superior texture and taste,” Peter Burns, president and CEO of One Brands, said. “This is just one example of our ongoing commitment to innovation and providing the best protein snacks on the market.”

“As a leader in the protein category, we are always creating, testing and innovating – we go all the way with everything we do. One Basix took us years to get exactly right and we are proud to introduce it as a naturally sweetened protein option,” added Ron McAfee, founder of One Brands. “The deep relationship between One and our customers keeps us focused on delivering extraordinary products.”

Utilizing stevia, a leafy green plant native to South America, as a sweetening agent, One Basix Bars offer a new, simplified take on One Bars. They are free of gluten, sugar alcohols and sucralose and are certified Kosher.

One Basix will be available starting in May at select specialty stores and various gyms nationwide.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Triple W develops novel incontinence wearable device

BY Michael Johnsen

Triple W, a San Diego- based startup company, on Monday announced the development of the first connected incontinence wearable device that can track the progression of bladder movements using non-invasive ultrasonic sensors.

“Health services globally are struggling with the burden of growing and aging populations and continue to put more emphasis on patients and caregivers to monitor their own well-being,” Atsushi Nakanishi, president and CEO Triple W, said. “I believe the potential for a device like DFree in the U.S. is vast and we are looking forward to making the product available later this year. Our mission is to help people with incontinence regain dignity and confidence so that they can live their life to the fullest.”

The device will help elderly and disabled people who suffer from incontinence by notifying them when they will need to go to the bathroom. As a result, users no longer have to worry about accidents and can often forgo the embarrassment of wearing diapers.

The device is placed on the lower abdomen and uses ultrasonic sensors to monitor the change in bladder size. The data collected is then sent to a server where it is analyzed using a patented algorithm. The notification goes to a smartphone or tablet used by the patient, nurse or caregivers, and informs them when it is necessary to go to the bathroom.

Triple W has won numerous innovation awards with the most recent one being the Pitch Innovation Prize by AgeingFit, an organization accelerating innovation for the senior market. Triple W will also be exhibiting the DFree at Medtrade, an international trade show and conference for the home healthcare industry, held in Las Vegas this month.

The company is currently exploring new partnership opportunities with U.S. retailers and distributors, as well as collaborative opportunities with other U.S. healthcare companies.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Perrigo gains FDA approval for Mucinex DM

BY Michael Johnsen

Perrigo on Tuesday announced it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide extended-release tablets, 1200 mg/60 mg).

“This final approval and upcoming launch is an important accomplishment for our OTC business,” Jeff Needham, executive vice president and president, Consumer Healthcare Americas, for Perrigo, said. “Key product launches like Perrigo’s store brand equivalent of Mucinex® DM Maximum Strength provide our customers and consumers with high quality, value alternatives in important treatment categories.”

Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Retail sales of the cough-cold product for the last 12 months were approximately $128 million as measured by IRI, Perrigo reported.

The company is finalizing plans to launch Perrigo’s wholly owned store brand equivalent of Mucinex DM Maximum Strength for the 2018 cough-cold season.

This product will be packaged and marketed as a retailer own brand and will provide consumers with a value alternative to Mucinex DM Maximum Strength.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?